Fewer than 4% of eligible women worldwide get an annual mammogram. It isn’t for lack of need — cost, access, modesty, and the exam itself all stand in the way.
women worldwide lack access to regular cancer screening.
Breast cancer is the most common cancer in women worldwide — and the population most in need of screening is the one least likely to have access to it.
Even where mammography exists, capacity falls far short of the eligible population — in every market, not only low-resource ones.
Swipe to see all regions
| Worldwide | USA | India | China | |
|---|---|---|---|---|
| Women over age 40 | ~1.6B | ~56M | ~250M | ~350M |
| Mammograms performed / year | ~60M | ~25M | ~7M | ~7.5M |
| Est. annual coverage | ~4% | ~45% | <3% | ~2% |
Sources: Lancet, 2018; GE Healthcare, 2017; WCRF; Ameri Research Inc., 2018.
MammoAlert trades a fixed imaging center and a radiologist for a portable device and a finger-prick sample — so early detection can reach clinics, pharmacies, and community health posts mammography infrastructure will never economically reach.
Swipe to see the full comparison
| Mammography | MammoAlert™ | |
|---|---|---|
| Equipment needed | Fixed X-ray imaging unit — calibration & upkeep | Portable point-of-care device |
| Sample | Breast X-ray imaging | Finger-prick blood sample |
| Who can run it | Trained technologist; radiologist required to read results | Any trained healthcare worker; AI-powered result |
| Time to result | Often days, pending radiologist read | Under 30 minutes |
| Where it can go | Hospitals & accredited imaging centers, mostly urban | Clinics, pharmacies, community posts, mobile units |
The world’s first globally deployable diagnostic platform for early cancer detection — starting with breast cancer, built to expand to pan-cancer.
Five complementary biomarkers, interpreted with explainable AI.
Low-cost and portable — simple enough for any trained worker to run in clinics, hospitals, pharmacies, and community settings everywhere.
Built to keep learning and to extend to more cancer types over time.
Designed for accessible, affordable detection in developed and emerging markets alike.
Built on nearly two decades of biomarker research and clinical development.
Reaching underserved women doesn’t have to mean building more imaging centers or training more radiologists.
Extend detection capacity without new imaging equipment or radiologist hours — MammoAlert triages risk in under 30 minutes to help prioritize who needs follow-up imaging.
Expand national early-detection programs into rural and underserved regions via mobile units, clinics, and community campaigns — no imaging center required.
Global cancer diagnostics market
Breast cancer detection segment
A team with deep IVD experience, spanning product, regulatory, and finance — several of whom have taken diagnostics companies through prior exits.
Early proof-of-concept deployments and independent physician perspectives on the need for accessible breast cancer detection.
An early field look at accessible breast cancer detection in China.
Watch on YouTubeAn early field look at accessible breast cancer detection in India.
Watch on YouTubeA clinical perspective on the need for accessible breast cancer detection.
Watch on YouTubeSanjeev Saxena on the need for accessible breast cancer detection.
Watch on VimeoA TiEcon 2017 panel on women’s health and access to cancer detection.
Watch on YouTubeAn early radio interview on the vision behind Harae Dx.
Watch on YouTubeA conversation on bringing accessible cancer detection to India.
Watch on YouTubePress coverage, founder features, and research on the mission behind Harae Dx.
A YesPress feature on the 30-year mission behind Harae Dx and MammoAlert.
Read the ProfileHarae Dx Corp. on how AI and microfluidics are converging to advance cancer diagnostics.
Read on LinkedInSanjeev Saxena on why early cancer detection is critical to improving patient outcomes.
Read on LinkedInBest Startup California’s spotlight on standout startups based in Pleasanton, California.
Read on LinkedInSanjeev Saxena on POC Medical Systems’ MammoAlert-Pandora CDx blood test and the shift toward diagnostic-led care.
Read the FeatureExpress Healthcare profiles POC Medical Systems’ approach to point-of-care diagnostics.
Read the FeatureBioSpectrum Asia on the outlook for the cancer diagnostics industry amid an aging global population.
Read the ReportA peer-reviewed mini-review (PMC/NIH) on AI-driven approaches to expanding breast cancer screening access in India.
Read the StudyScienceAlert reports on a Columbia University study showing breast cancer rates climbing among American women under 40.
Read the Article
